Applied BioCode is a public company traded on the Taiwan Emerging Market Exchange that designs, develops, manufactures, and commercializes multiplex testing products for the $52 billon In-Vitro diagnostics market.
Their Barcoded Magnetic Bead (BMB) technology and detection systems facilitate the development of highly multiplexed nucleic acids or protein detection assays. The BMB technology offers up to 4,096 unique digital barcodes for multiplex analysis with unmatched decoding accuracy.
Applied BioCode's In-Vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. Applied BioCode partners with a variety of other diagnostic companies with applications that include infectious diseases, autoimmune diseases, allergies, transplantations, transfusions, hepatitis, and the gut microbiome.
In addition to the In-Vitro diagnostics market, Applied BioCode also partners with companies to develop applications for other areas of the diagnostics industry including the life science research, agricultural testing, and veterinary markets.